Drug Profile
CIB 01
Alternative Names: CIB01Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Kao Corporation
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Skin-disorders in Japan (Topical)
- 19 Sep 2018 Kao Corporation completes a phase I trial in Skin disorders in Japan (Topical) (UMIN000029581)
- 20 Oct 2017 Phase-I clinical trials in Skin disorders in Japan (Topical) (UMIN000029581)